Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Inclusion Criteria:

• History of cardiovascular (CV) disease, high CV risk, or estimated glomerularfiltration rate (eGFR) ≥30 to <60 mL/min/1.73m^2

• Mean seated office SBP ≥140 mmHg and ≤170 mmHg

• 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM

• Must be on stable therapy with 2 to 4 classes of antihypertensive medications

Exclusion Criteria:

• Secondary hypertension

• Orthostatic hypotension

• Proteinuria >3 g/day

• Serum potassium >4.8 milliequivalents per liter (mEq/L)